DP Diagnostic Products

Diagnostic Products Corporation (NYSE:DP) today announced that they have recently begun shipping the Immunoassay Workcell, a high volume automated immunoassay testing system. An extensive testing program and a controlled launch plan have proven the reliability of the system and demonstrated its ability to significantly improve laboratory productivity. DPC's Sample Management System (SMS) is used to create the Immunoassay Workcell, which combines two IMMULITE 2000 systems, two IMMULITE 2500 systems, or a combination of the two systems. The Immunoassay Workcell is designed to meet the needs of the high volume testing facilities to provide flexibility with productivity for immunoassay testing. The system operator now has access to 48 different assays and 9,600-reagent tests from a single sample entry point, allowing up to 5 hours of usable walk-away time. A unique advantage of the Immunoassay Workcell is that it processes patient samples on a tube-by-tube basis, as opposed to the more conventional rack loading technique. The Immunoassay Workcell also simplifies operation by allowing the laboratory technician to interface with the entire system via a single workstation. "This is great news for both DPC and our customers," said Sidney A. Aroesty, President, COO, DPC. "With approximately 4,000 IMMULITE 2000 and IMMULITE 2500 systems placed worldwide, it is clear that these systems are meeting the needs of many laboratories in a variety of testing environments. The addition of our Immunoassay Workcell will offer even more flexibility in processing immunoassay tests and will increase productivity and provide operators more usable walk-away time to perform other duties in the lab. The fact that the SMS can be linked to a track-based laboratory automation system further expands our flexibility to meet the needs of our customers. This is the 'powerhouse' in the family of IMMULITE systems." About Diagnostic Products Corporation Diagnostic Products Corporation, founded in 1971, is the global leader dedicated exclusively to immunodiagnostics. DPC's product menu includes over 75 immunoassays and more than 365 specific allergens and allergy panels. In addition, DPC addresses the chemistry and laboratory automation testing needs of its customers through partnerships with manufacturers of chemistry systems and reagents. The combined chemistry and immunoassay menu is one of the largest and most diversified available, covering most laboratory tests requested. DPC also designs and manufactures automated laboratory instrumentation, which provides fast, accurate results while reducing labor and reagent costs. DPC sells its products to hospitals, clinics and laboratories in more than 100 countries. Additional Company information can be found on DPC's website at www.dpcweb.com. Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially. These factors include the effects of governmental or other actions relating to the FDA's decision that its Application Integrity Policy should be applied to the Company or relating to the Company's Chinese affiliate; the rate of customer demand for the Company's products; the Company's ability to successfully market new and existing products; its dependence on certain suppliers; domestic and foreign government regulation; its ability to keep abreast of technological innovations and to translate them into new products; competition; political and economic instability in certain markets including the movements of foreign currencies relative to the dollar; and other risks and uncertainties disclosed from time to time in the Company's SEC reports and filings.